Physician profile
Kristopher Lepere
NPI 1568461317
$1,777.56
in general payments reported to CMS, 2019-2025
17 companies · $275 in 2025
The $275 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $578 · 2020: $79.16 · 2021: $93.36 · 2022: $263 · 2023: $149 · 2024: $340 · 2025: $275.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $744 · Education: $19.97.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $743.85 |
| Education | $19.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Veloxis Pharmaceuticals, INC. | $625.40 | 2019-2025 | Envarsus |
| Astrazeneca Pharmaceuticals Lp | $377.45 | 2019-2025 | Farxiga, Lokelma |
| Horizon Therapeutics Plc | $125.00 | 2019 | |
| Alexion Pharmaceuticals, INC. | $100.86 | 2021-2024 | Ultomiris |
| Genzyme Corporation | $95.79 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $80.06 | 2024-2025 | Livtencity |
| Novartis Pharmaceuticals Corporation | $73.58 | 2023-2025 | |
| Travere Therapeutics, INC. | $58.74 | 2024 | |
| Eurofins Viracor, LLC | $52.98 | 2021-2025 | |
| Mallinckrodt Enterprises LLC | $31.50 | 2019 | |
| Calliditas Therapeutics US INC. | $28.67 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $23.56 | 2021 | |
| Abbott Laboratories | $22.73 | 2025 | Freestyle Libre 3 |
| Dexcom, INC. | $21.48 | 2024 | Dexcom G6 Transmitter |
| Kci USA, INC. | $20.96 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| La Jolla Pharmaceutical Company | $20.40 | 2019 | |
| Merck Sharp & Dohme LLC | $18.40 | 2025 | Prevymis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristopher Lepere listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.